A later report, however, did state that anti-tumor activity elicited by CRP in liposomes could be abrogated by treating peritoneal exudate cells with anti-Thy 1.2 (reacting with a marker on T-lymphocytes) or anti-asialo Gm1 (reacting with a marker on NK cells) and complement (33). The gene discussed is CRP; the disease is neoplasm.